Inter-individual Variability in Propofol Pharmacokinetics in Preterm and Term Neonates
Karel Allegaert,Mariska Y. M. Peeters,René Verbesselt,Dick Tibboel,Gunnar Naulaers,J.N. de Hoon,Catherijne A. J. Knibbe +6 more
TLDR
PMA and PNA contribute to the inter-individual variability of propofol clearance with very fast maturation of clearance in neonatal life and implicates that preterm neonates and neonates in the first week of postnatal life are at an increased risk for accumulation during either intermittent bolus or continuous administration of prop ofol.Abstract:
Background To document covariates which contribute to inter-individual variability in propofol pharmacokinetics in preterm and term neonates. Methods Population pharmacokinetics were estimated (non-linear mixed effect modelling) based on the arterial blood samples collected in (pre)term neonates after i.v. bolus administration of propofol (3 mg kg−1, 10 s). Covariate analysis included postmenstrual age (PMA), postnatal age (PNA), gestational age, weight, and serum creatinine. Results Two hundred and thirty-five arterial concentration–time points were collected in 25 neonates. Median weight was 2930 (range 680–4030) g, PMA 38 (27–43) weeks, and PNA 8 (1–25) days. In a three-compartment model, PMA was the most predictive covariate for clearance (P 0.001). Conclusions PMA and PNA contribute to the inter-individual variability of propofol clearance with very fast maturation of clearance in neonatal life. This implicates that preterm neonates and neonates in the first week of postnatal life are at an increased risk for accumulation during either intermittent bolus or continuous administration of propofol.read more
Citations
More filters
Journal ArticleDOI
Prevention and management of procedural pain in the neonate: An update
Kristi L. Watterberg,James J. Cummings,William E. Benitz,Eric C. Eichenwald,Brenda B. Poindexter,Dan L. Stewart,Susan W. Aucott,Jay P. Goldsmith,Karen M. Puopolo,Kasper S. Wang,Joseph D. Tobias,Rita Agarwal,Corrie T M Anderso,Courtney Hardy,Anita Honkanen,Mohamed A. Rehman,Carolyn F. Bannister +16 more
TL;DR: Every health care facility caring for neonates should implement a pain-prevention program that includes strategies for minimizing the number of painful procedures performed and a pain assessment and management plan.
Journal ArticleDOI
Propofol: a review of its role in pediatric anesthesia and sedation
TL;DR: There is no direct evidence in humans for propofol-induced neurotoxicity to the infant brain; however, current concerns of neuroapoptosis in developing brains induced by prop ofol persist and continue to be a focus of research.
Journal ArticleDOI
Pain management in newborns.
TL;DR: Local/topical anesthetics, opioids, NSAIDs/acetaminophen and other sedative/anesthetic agents can be incorporated into NICU protocols for managing moderate/severe pain or distress in all newborns.
Journal ArticleDOI
Tips and Traps Analyzing Pediatric PK Data
TL;DR: This review identifies some of the pitfalls of modeling techniques associated with pitfalls and suggests ideas to circumvent or investigate these hazards.
Journal ArticleDOI
Optimizing pediatric dosing: a developmental pharmacologic approach.
Gail D. Anderson,Anne M. Lynn +1 more
TL;DR: It is revealed that children need weight‐corrected doses that are substantially higher than adult doses for drugs that are metabolically eliminated solely by the specific cytochrome P450 isoenzymes CYP1A2, CYP2C9, and CYP3A4.
References
More filters
Journal ArticleDOI
Developmental Pharmacology — Drug Disposition, Action, and Therapy in Infants and Children
Gregory L. Kearns,Susan M. Abdel-Rahman,Sarah W. Alander,Douglas L. Blowey,J. Steven Leeder,Ralph E. Kauffman +5 more
TL;DR: This review examines the developmental changes that profoundly affect the responses of children to medications and related therapies in the very young.
Journal ArticleDOI
Metabolic acidosis and fatal myocardial failure after propofol infusion in children: five case reports.
T. J. Parke,J. E. Stevens,Andrew S.C. Rice,C. L. Greenaway,R.J. Bray,P. J. Smith,C. S. Waldmann,C. Verghese +7 more
TL;DR: Although the exact cause of death in these children could not be defined, propofol may have been a contributing factor.
Journal ArticleDOI
Developmental pharmacokinetics of morphine and its metabolites in neonates, infants and young children.
TL;DR: M3G is the predominant metabolite of morphine in young children and total body morphine clearance is 80% that of adult values by 6 months, and appeared to be similar to that described for glomerular filtration rate maturation in infants.
Journal ArticleDOI
Morphine metabolism in children.
TL;DR: It is suggested that morphine glucuronidation capacity is enhanced after the neonatal period, and there was no difference in the M3G/M6G ratio in children and neonates, indicating a parallel development of both glucuronidated pathways.
Journal ArticleDOI
Propofol compared with the morphine, atropine, and suxamethonium regimen as induction agents for neonatal endotracheal intubation: a randomized, controlled trial.
Satish Ghanta,Mohamed E Abdel-Latif,Mohamed E Abdel-Latif,Kei Lui,Kei Lui,Hari Ravindranathan,John Awad,Ju Lee Oei,Ju Lee Oei +8 more
TL;DR: Propofol is more effective than the morphine, atropine, and suxamethonium regimen as an induction agent to facilitate neonatal nasal endotracheal intubation and the shorter duration of action would be advantageous in a compromised infant.